469 related articles for article (PubMed ID: 25319097)
1. Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.
Mehta DC; Short JL; Hilmer SN; Nicolazzo JA
Pharm Res; 2015 Mar; 32(3):819-39. PubMed ID: 25319097
[TBL] [Abstract][Full Text] [Related]
2. Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
Liu CC; Yamazaki Y; Heckman MG; Martens YA; Jia L; Yamazaki A; Diehl NN; Zhao J; Zhao N; DeTure M; Davis MD; Felton LM; Qiao W; Li Y; Li H; Fu Y; Wang N; Wren M; Aikawa T; Holm ML; Oue H; Linares C; Allen M; Carrasquillo MM; Murray ME; Petersen RC; Ertekin-Taner N; Dickson DW; Kanekiyo T; Bu G
Alzheimers Dement; 2020 Oct; 16(10):1372-1383. PubMed ID: 32827351
[TBL] [Abstract][Full Text] [Related]
3. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
[TBL] [Abstract][Full Text] [Related]
4. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
Kalra J; Khan A
Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
[TBL] [Abstract][Full Text] [Related]
5. Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.
Yamazaki Y; Shinohara M; Shinohara M; Yamazaki A; Murray ME; Liesinger AM; Heckman MG; Lesser ER; Parisi JE; Petersen RC; Dickson DW; Kanekiyo T; Bu G
Brain; 2019 Apr; 142(4):1077-1092. PubMed ID: 30770921
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Hit Compounds Identified from High-throughput Screening for their Effect on Blood-brain Barrier Integrity and Amyloid-β Clearance: In Vitro and In Vivo Studies.
Elfakhri KH; Duong QV; Langley C; Depaula A; Mousa YM; Lebeouf T; Cain C; Kaddoumi A
Neuroscience; 2018 May; 379():269-280. PubMed ID: 29596966
[TBL] [Abstract][Full Text] [Related]
7. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.
Yamazaki Y; Kanekiyo T
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142
[TBL] [Abstract][Full Text] [Related]
8. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.
Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C
Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049
[TBL] [Abstract][Full Text] [Related]
9. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery.
Sharma HS; Castellani RJ; Smith MA; Sharma A
Int Rev Neurobiol; 2012; 102():47-90. PubMed ID: 22748826
[TBL] [Abstract][Full Text] [Related]
10. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.
Biron KE; Dickstein DL; Gopaul R; Jefferies WA
PLoS One; 2011; 6(8):e23789. PubMed ID: 21909359
[TBL] [Abstract][Full Text] [Related]
11. Cellular junction dynamics and Alzheimer's disease: a comprehensive review.
Asghari K; Niknam Z; Mohammadpour-Asl S; Chodari L
Mol Biol Rep; 2024 Feb; 51(1):273. PubMed ID: 38302794
[TBL] [Abstract][Full Text] [Related]
12. The blood brain barrier in Alzheimer's disease.
Chakraborty A; de Wit NM; van der Flier WM; de Vries HE
Vascul Pharmacol; 2017 Feb; 89():12-18. PubMed ID: 27894893
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
[TBL] [Abstract][Full Text] [Related]
14. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase.
Provias J; Jeynes B
Curr Neurovasc Res; 2008 Aug; 5(3):199-205. PubMed ID: 18691078
[TBL] [Abstract][Full Text] [Related]
15. Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.
Kook SY; Hong HS; Moon M; Ha CM; Chang S; Mook-Jung I
J Neurosci; 2012 Jun; 32(26):8845-54. PubMed ID: 22745485
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
Banks WA
Adv Drug Deliv Rev; 2012 May; 64(7):629-39. PubMed ID: 22202501
[TBL] [Abstract][Full Text] [Related]
17. Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease.
Sagare AP; Bell RD; Zlokovic BV
J Alzheimers Dis; 2013; 33 Suppl 1(0 1):S87-100. PubMed ID: 22751174
[TBL] [Abstract][Full Text] [Related]
18. [Role of the blood-brain barrier in Alzheimer's disease].
Gosselet F; Candela P; Cecchelli R; Fenart L
Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
[TBL] [Abstract][Full Text] [Related]
19. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.
Kuo YC; Chen CL; Rajesh R
Acta Biomater; 2019 Mar; 87():207-222. PubMed ID: 30716553
[TBL] [Abstract][Full Text] [Related]
20. Annexin A1 restores Aβ
Park JC; Baik SH; Han SH; Cho HJ; Choi H; Kim HJ; Choi H; Lee W; Kim DK; Mook-Jung I
Aging Cell; 2017 Feb; 16(1):149-161. PubMed ID: 27633771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
